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ABSTRACT
Transcription factors have been considered undrug-
gable, but this paradigm has been recently chal-
lenged. DNA binding natural product mithramycin
(MTM) is a potent antagonist of oncogenic tran-
scription factor EWS–FLI1. Structural details of MTM
recognition of DNA, including the FLI1 binding se-
quence GGA(A/T), are needed to understand how
MTM interferes with EWS–FLI1. We report a crystal
structure of an MTM analogue MTM SA–Trp bound
to a DNA oligomer containing a site GGCC, and
two structures of a novel analogue MTM SA–Phe in
complex with DNA. MTM SA–Phe is bound to sites
AGGG and GGGT on one DNA, and to AGGG and
GGGA(T) (a FLI1 binding site) on the other, revealing
how MTM recognizes different DNA sequences. Un-
expectedly, at sub-micromolar concentrations MTMs
stabilize FLI1–DNA complex on GGAA repeats, which
are critical for the oncogenic function of EWS–FLI1.
We also directly demonstrate by nuclear magnetic
resonance formation of a ternary FLI1–DNA–MTM
complex on a single GGAA FLI1/MTM binding site.
These biochemical and structural data and a new
FLI1–DNA structure suggest that MTM binds the mi-
nor groove and perturbs FLI1 bound nearby in the
major groove. This ternary complex model may lead
to development of novel MTM analogues that selec-
tively target EWS–FLI1 or other oncogenic transcrip-
tion factors, as anti-cancer therapeutics.
INTRODUCTION
Specific targeting of transcription factors by small
molecules is an attractive concept that has been difficult to
realize. Recently, mithramycin (MTM; Figure 1), a DNA
binding aureolic acid natural product, was identified in
high-throughput screening of 50 000 small molecules as
a highly potent (low-nanomolar) and modestly selective
inhibitor of abnormal oncogenic transcription factor
EWS–FLI1 in Ewing sarcoma (ES) (1). ES is a rare devas-
tating cancer affecting mostly children and young adults
that is caused by EWS–FLI1 in the majority of ES patients.
Because MTM antagonizes EWS–FLI1 without affecting
its expression level (1), MTM likely directly interferes with
the EWS–FLI1 function on DNA. Due to its anti-tumor
activity caused by the potent inhibition of EWS–FLI1 in
mouse ES xenografts, MTM recently underwent a phase
I/II clinical trial as an ES therapeutic (National Cancer
Institute clinical trial NCT01610570), where toxicity was
observed at doses below efficacious doses of this agent.
Because of the off-target toxicity, more selective anti-ES
analogues of MTM are needed.
EWS–FLI1 is an abnormal fusion of parts of two pro-
teins (EWS and FLI1), containing the DNA binding do-
main (DBD) of FLI1 (2,3), which is a result of a chro-
mosomal translocation. The FLI1 DBD is critical for the
transcription and oncogenic transformation functions (4)
of EWS–FLI1. Because ES cells, but not other cells, con-
tain EWS–FLI1, it is an attractive target for development
of novel anti-cancer agents (5–7). MTM analogues with im-
proved selectivity against this fusion would have a wider
therapeutic window than MTM does. analogues of MTM
with modified B- and E-sugar moieties and the 3-side
chain (see the atom numbering and group nomenclature
in Figure 1) were recently shown to have lower toxicity or
higher anti-ES potency in vitro and in mouse ES xenografts
(8). Recently, semi-synthetic MTM analogues of the 3-side
chain were demonstrated to have improved potency against
non-small lung cancer cells A549 (9) and improved anti-
tumor activity and toxicity in colon and melanoma mouse
xenograft models (10). This 3-side chain of MTM was pre-
viously proposed not to be involved in direct DNA con-
tacts (11); therefore, its modifications may not interfere sig-
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Figure 1. Chemical structures of mithramycin, its analogues and chromomycin A3.
nificantly with DNA recognition properties of MTM ana-
logues. Indeed, we demonstrated that a recently developed
MTM analogue, MTM SA–Trp, had a similar DNA se-
quence preference and binding affinity to those of MTM
(12). Nevertheless, we also showed in the same study that
3-side chain substitutions could modulate the DNA bind-
ing affinity of the analogues by as much as ∼20-fold. De-
tailed mechanistic understanding of MTM–DNA binding
and inhibition of EWS–FLI1 is necessary for development
of highly selective MTM analogues that would specifically
target EWS–FLI1. Principles of such design may then also
be applied to design MTM analogues as chemical probes
for selective targeting of other transcription factors.
MTM is a non-intercalatingDNAbindingmolecule (11).
We hypothesized that the disruption of EWS–FLI1 func-
tion byMTM is due to some effect of MTM on FLI1 DBD
at oncogenic promoters. MTM binds in the minor groove
of DNA as a dimer, in which the two MTM monomers are
coordinated by a divalent metal ion (11,13–15). Pioneer-
ing solution structural studies of MTM bound to palin-
dromic GGCC DNA in the Patel laboratory by a combi-
nation of nuclear magnetic resonance (NMR) and molecu-
lar dynamics elegantly demonstrated that an MTM dimer
recognized the central GC, so that the 2-fold dyad symme-
try of the MTM dimer matched that of the DNA (11,16).
Due to the intrinsic limitations of isotopic labeling in this
and similar methods, the DNA conformation cannot be un-
ambiguously resolved and needs to be assumed. Another
structurally characterized aureolic acid natural product,
chromomycin A3, contains O-methylated or O-acetylated
groups in three out of five sugar moieties as well as nu-
merous differences from MTM in the stereochemistry of
the sugars and its glycosylic linkages (Figure 1). A crys-
tal structure of chromomycin in complex with a similar
GGCC-containing DNA oligomer was consistent with the
basic observations made from the MTM–DNA solution
structure (17). This structure revealed for the first time the
octahedral coordination of the divalent metal ion by the
chromomycin monomers and two water molecules. How-
ever, the chromomycin–DNA crystal structure exhibited
significant differences from the previously reported solu-
tion structures of both MTM– and chromomycin–DNA
complexes (18), in DNA conformations and the disposi-
tions of the chromophore rings, presumably due to the lim-
itations of the NMR data (17) as well as chemical differ-
ences. Therefore, these aspects of MTM–DNA complexes
remain unclear. We have recently established that a DNA
motif X(G/C)(G/C)X is necessary and sufficient for high-
affinity binding by MTM (12). Notably, the recognition se-
quence for FLI1 and other related (ETS-family) transcrip-
tion factorsGGA(A/T) is a strongMTMbinding sequence,
but is not a palindrome. We and others have demonstrated
that XGGX is a particularly high-affinity sequence (12,19).
Therefore, another critical question to be addressed in elu-
cidating the MTMmode of action and DNA recognition is
how MTM binds non-palindromic DNA sequences.
In this work, we harnessed the structural variation of
novel semi-syntheticMTM analogues to perform a detailed
structural investigation of MTM–DNA complex forma-
tion for different DNA sequences and probed the effect of
MTMs on the stability of FLI1–DNA complex. Together
with a new crystal structure of FLI1 DBD–DNA complex,
these studies led us to propose a structural model of MTM
antagonism of EWS–FLI1.
MATERIALS AND METHODS
Synthesis of MTM SA–Trp and MTM SA–Phe
MTMSA–Trp was produced and characterized as reported
recently (12). To synthesizeMTMSA–Phe, we used an anal-
ogous PyBop coupling reaction, except for the use of L-Phe
methyl ester instead of L-Trp methyl ester in the synthesis.
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MTM SA–Phe was characterized by NMR spectroscopy
and liquid chromatography–mass spectrometry (LCMS)
analysis (Supplementary Figures S1–5 and Table S1). Prior
to their use in the crystallization and binding assays, MTM
and its analogueueues were dissolved in dimethyl sulfoxide
(DMSO) at 20 mM.
Crystallization, data collection and structure determination
for MTM analogue–DNA complexes
Single-stranded palindromic DNA oligonucleotides
5′-AGAGGCCTCT-3′, 5′-AGGGTACCCT-3′, 5′-
AGGGATCCCT-3′ were purchased from IDT (Coralville,
IA, USA). The double-stranded oligomers were formed by
dissolving each DNA to 2 mM in 10 mM Tris–HCl pH 8.0
(pH adjusted at room temperature), heating the solutions
to 95◦C and slowly cooling them to 4◦C. The crystals
of MTM SA–Trp- AGGGTACCCT, MTM SA–Phe-
AGGGTACCCT and MTM SA–Phe-AGGGATCCCT
were grown by vapor diffusion in 1 l hanging drops
containing 10 mM sodium cacodylate pH 6.0, 4 mM zinc
acetate dihydrate, 0.85 mM DNA, 1.8 mM MTM SA–Trp
or MTM SA–Phe, 2 mM spermine incubated against
35% v/v 2-methyl-2,4-pentanediol at 21◦C. The crystals
were taken directly from these drops and frozen in liquid
nitrogen by quick immersion.
X-ray diffraction data for the crystals of the MTM SA–
Trp–DNA complex were collected at 100 K at sector 22-ID
(SER-CAT) of the Advanced Photon Source (APS) of the
Argonne National Laboratory (Argonne, IL, USA). The
data for the crystals of the MTM SA–Phe complexes were
collected at sector 21-ID (Life Sciences–Collaborative Ac-
cess Team; LS–CAT) at the same facility. Data indexing, in-
tegration and scaling were performed with HKL2000 (20).
The crystal structures were determined by using the anoma-
lous signal from bound Zn2+ ions by the single–wavelength
anomalous dispersion (SAD) method with Phenix suite
(21). The Zn2+ sites were located by the HySS module
(22) and then used for phasing by Phaser (23). The pe-
riodic electron density for the DNA backbone and par-
tial density for the bases and the MTM analogues was
well discernible in the experimental map and allowed us
to build an initial DNA model. Subsequent rounds of re-
finement with Refmac (24) and model building with Coot
(25) improved the map quality and allowed us to complete
the DNA models and build MTM SA–Trp and MTM–
Phe. The data collection and refinement statistics are given
in Supplementary Table S2. The structures of MTM SA–
DNA, MTM SA–Phe-AGGGTACCCT and MTM SA–
Phe–AGGGATCCCT were deposited in the Protein Data
Bank with accession codes 5JVW, 5JW0 and 5JW2, respec-
tively.
Cloning, expression and purification of the DNA binding do-
main of FLI1
A pET28a plasmid encoding a EWS–FLI1 fusion (26) was
a kind gift from Dr Jeffrey Toretsky. This vector served
as a template for polymerase chain reaction (PCR) ampli-
fication of the region encoding the FLI1 DBD (residues
276–375), by using primers 5′-ATCAACCACATATGCC
TGGAAGCGGGCAGATCCAGC-3′ and 5′-
ATCCTCGAGCTACTCGGTCGGATGTGGCTGCAG-
3′. The PCR product, after appropriate processing, was
inserted into a modified pET19b-pps vector (27) between
NdeI and XhoI restriction sites. The resulting protein
product contained an N-terminal decahistidine tag cleav-
able by Prescission protease (GE Healthcare). The protein
was expressed and purified by using a recently published
protocol (28) with minor modifications, as follows. The
protein was expressed in BL21(DE3)-RIL cells at 13◦C
for 18 h upon induction with 1 mM IPTG and purified
on Ni-IMAC HisTrap FF column (GE Healthcare) and
washed thoroughly with 1 M NaCl to remove possible
contaminating DNA prior to the elution. The tag was
removed by overnight cleavage with PreScission protease
at 4◦C followed by further purification on a size-exclusion
Sephacryl S-200 column (GEHealthcare) equilibrated in 40
mM Tris–HCl pH 8.0 (pH adjusted at room temperature),
0.15 M NaCl and 2 mM -mercaptoethanol. The fractions
containing protein were pooled and concentrated using
an Amicon Ultra-15 centrifugal filter device (Millipore)
to 2 mg/ml. This preparation was then used to form and
further purify protein–DNA complexes for crystallization.
For DNA binding studies, we used a previously reported
construct of FLI1 DBD (residues 259–399), expressed and
purified analogously (28).
Double-stranded 11-bp DNA oligomer consisting of
complementary strands 5′-GACCGGAAGTG-3′ and 5′-
CACTTCCGGTC-3′ (IDT) was annealed as described pre-
viously (28). The double-stranded oligomer was added to
the purified FLI1 DBD at the 1.2:1 DNA: FLI1 molar ra-
tio. This protein-DNAmixture was then diluted 5-fold with
a buffer not containing NaCl (40 mMTris–HCl pH 8.0 and
2 mM -mercaptoethanol), incubated on ice for 15 min and
then purified on a size-exclusion Sephacryl S-200 column
equilibrated in 20 mMTris–HCl pH 8.0. An elution peak at
a position distinct from that of protein alone represented the
protein–DNA complex. The peak fractions were pooled,
concentrated to ∼20 mg/ml. This preparation was flash-
frozen in liquid nitrogen, and stored at −80◦C for crystal-
lization.
Crystallization, data collection and crystal structure determi-
nation for the FLI1 DBD–DNA complex
The crystals of the FLI1 DBD–DNA complex were grown
at 21◦C by vapor diffusion in hanging drops containing a
mixture of 1 l of the concentrated protein–DNA complex
and 1l of the reservoir solution (1.6M ammonium sulfate,
0.1 M sodium acetate pH 4.6). The crystals were gradually
transferred into the cryoprotectant solution (1.6 M ammo-
nium sulfate, 0.1 M sodium acetate, pH 4.6 and 28% su-
crose) and then frozen in liquid nitrogen by quick immer-
sion. The X-ray diffraction data were collected at 100 K at
the sector 22-ID (SER-CAT) of theAPS and processedwith
HKL2000 (20). The structure was determined by molecu-
lar replacement with programMOLREP (29) with our pre-
viously published structure of FLI1 DBD–DNA (PDB ac-
cession code 5E8I; (28)) as a search model. The structure
was then iteratively rebuilt and refined with COOT (25) and
REFMAC (24), respectively. The data collection and refine-
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ment statistics are given in Supplementary Table S3. The
crystal structure of the FLI1 DBD–DNA complex and the
structure factor amplitudes were deposited in the Protein
Data Bank with accession code 5JVT.
DNA binding assays
A single-stranded DNA oligomer labeled with a 6-
carboxyfluorescein (6FAM) at the 5′-end 5′-6FAM-
AA(GGAA)6-3′ was annealed with its complementary
unlabeled oligomer (both from IDT) as described above.
The binding mixture contained 50 nM of this double-
stranded DNA oligomer, 500 nM FLI1 DBD (residues
259–399) and MTM or its analogue (at a specified con-
centration) in the binding buffer (20 mM Tris–HCl, pH
8.0 (adjusted at room temperature), 50 mM NaCl, 10 mM
MgCl2). The mixture was incubated for 15 min at 22◦C.
Heparin was then added to the final concentration of 7.5
mg/ml and the mixture was incubated for 10 min before
fluorescence measurements. The fluorescence polarization
measurements were carried out in 96-well plates on a
SpectraMax M5 microplate reader (Molecular Devices), at
excitation and emission wavelengths of 495 and 520 nm,
respectively.
NMR experiments
The 15N-labeled FLI1 DBD was expressed in M9 mini-
mal media with 15N-labeled NH4Cl as the sole source of
nitrogen. The double-stranded DNA 12-mer TTGAAG-
GAAGAG was prepared as described above. The HSQC
spectra were acquired on a Bruker Avance III 500 spec-
trometer equipped with a 1H/13C/15N cryoprobe at the
University of Texas Health Science Center at San Anto-
nio Biomolecular NMR Core. NMR samples contained 1
mM 15N-labeled FLI1 alone or complexed with dsDNA (5′-
TTGAAGGAAGAG-3′), in 20 mM Tris–HCl, pH 7.0, 5
mM MgCl2, 5% D2O and 3% DMSO-d6, in the presence
and absence of 1 mMMTM SA–Trp.
RESULTS
Crystal structure ofMTMSA–Trp in complex with oligomer
AGAGGCCTCT
A crystal structure of MTM or an MTM–DNA complex
has not been obtained to date. Crystallization experiments
with MTM and DNA oligomers of different sequences and
sizes did not yield diffracting crystals. Our recently reported
analogue MTM SA–Trp and a novel analogue MTM SA–
Phe (Figure 1) ultimately have yielded high-quality crys-
tals, when in complex with DNA. We crystallized and de-
termined a structure of a complex of MTM SA–Trp with
a double-stranded palindromic 10-bp DNA oligomer 5′-
AGAGGCCTCT-3′ containing a central MTM recogni-
tion sequence GGCC (Figure 2A). The crystal structure
was refined at 2.0 A˚ resolution (Supplementary Table S2).
Zn2+ was used as a divalent metal mediating the dimer for-
mation of MTM SA–Trp (Figure 2A and B, Supplemen-
tary Figure S6), as Zn2+ was previously shown to stabi-
lize the dimer of MTM better than Mg2+, without affect-
ing other functions ofMTM (30,31). Moreover, anomalous
X-ray scattering by Zn2+ ions bound byMTM SA–Trp and
DNA was used to determine the crystal structure by single-
wavelength anomalous dispersion (SAD). The crystals con-
tained two nearly identical complexes of MTM SA–Trp–
DNAper asymmetric unit. Crystal packing interactions be-
tween complexes involved stacking of the indole ring of the
Trp residue of one MTM SA–Trp in the dimer against a
terminal A of the DNA of another complex in the crystal
(Supplementary Figure S7), which explained why this ana-
logue was critical for co-crystallization with DNA.
The dimer of MTM SA–Trp is bound to the DNA with
the same dyad symmetry as the DNA palindrome (Fig-
ure 2A). The dimer lies in the minor groove of the DNA,
with the sugar side chains in extended conformations. The
monomers in the dimer are oriented in an approximately
anti-parallel fashion relative to one another, so that the dis-
accharide side chain of each monomer points toward the
5′-end of the adjacent DNA strand. Even though the bind-
ing mode of MTM SA–Trp to DNA and MTM SA–Trp–
DNA interactions are generally similar to those in the so-
lution structure of MTM–DNA complex (where the same
DNA sequence was used) (11), there are differences in the
mutual disposition of the chromophore cores in the MTM
dimers and very large differences between the conforma-
tions of the saccharide side chains of MTM SA–Trp and
the DNA in our crystal structure and the respective confor-
mations of MTM and the presumed A-form DNA (of the
same sequence) in the solution structure. These differences
reflect the inaccuracy of the stereochemistry assumptions in
the solution structure necessitated by the intrinsic paucity of
theNMRdata, and not any deficiency of that elegantNMR
study. Likewise, differences between the previous structure
of chromomycin–DNA(TTGGCCAA) (17) and our struc-
ture of MTM SA–Trp–DNA complex are quite significant:
atomic positional differences of DNA backbones reach ∼4
A˚ and angle differences between the respective bases are
as large as ∼20–30◦. Similar differences were observed in
the natural product conformations. The DNA oligomers
are different in sequence outside of the core GGCC se-
quence; therefore, some of the conformational differences
outside of the core sequence may be due to the DNA se-
quence differences. Significant differences are present in the
GGCC regions and in theMTM chromophore dispositions
between the two structures. Most prominently, the minor
groove in the core GGCC region is wider by ∼2 A˚ in the
chromomycin–DNA structure and, if one superimposes one
of the two chromophore rings of the chromomycin and
MTM SA–Trp, the other two chromophore rings of the re-
spective dimers in the two structures form ∼20◦ angle to
one another, with the two chromomycin rings appearing as
a more obtuse wedge in the wider minor groove. The wider
minor groove in the chromomycin–DNA structure appears
to be needed to accommodate the bulkier acetyl groups on
the chromomycin sugar moieties, although the effects of
other chemical and stereochemical differences between the
two DNA binding molecules cannot be ruled out.
The 3-side chains bearing a Trp residue protrude out into
the solvent and do not interact with the DNA, except for a
water-mediated hydrogen bond between the carbonyl oxy-
gen adjacent to cores of some of MTM SA–Trp molecules
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Figure 2. Structure of MTM SA–Trp–DNA complex and the ligand–DNA interactions. (A) Crystal structure of MTM SA–Trp–DNA complex. The two
molecules of MTM analogue are shown as light-gray and dark-gray sticks, the DNA is in orange, the Zn2+ ion and its coordinating waters are shown as
red and yellow balls, respectively. (B) The zoomed-in view of the Zn2+ coordination and the GC motif recognition. (C) A schematic of the interactions in
the MTM SA–Trp–DNA complex.
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in the crystal and nearby DNA phosphate groups (Figure
2C). The sugar B moieties of each monomer also protrude
out of the minor groove, propped by hydrophobic interac-
tions with the deoxyribose moieties of G5/G6’ (Figure 2A
and C). The two tricyclic cores form a dimer through a co-
ordinated Zn2+ ion, which is bound to the O1 and O9 atoms
of each core and twowatermolecules (Figure 2B andC). All
six Zn2+-coordinating ligand atoms are located 2.0 A away
from the Zn2+, forming a perfect octahedral coordination
shell. The planes of the chromophore cores are at an 85◦
angle relative to one another, fitting snugly into the widemi-
nor groove (with the width of ∼14 A˚, as defined by 3DNA
program (32)) of this G/C rich DNA oligomer. The MTM
SA–Trp dimer interacts with a 6-base pair regionAGGCCT
of the 10-mer DNA, where the two nucleotides on the 5′-
end of this region on either strand do not interact with the
MTMSA–Trp (Figure 2C).With the exception of the E sug-
ars, each MTM SA–Trp molecule interacts only with one
DNA strand (Figure 2C). The chromophore and the di- and
the tri-sugar moieties of each monomer of MTM SA–Trp
make extensive hydrophobic contacts with the phosphodi-
ester backbone of the DNA and with the other monomer.
Specifically, the chromophore rings of each monomer inter-
act with C and D sugar moieties of the other monomer as
well as with the two deoxyribose moieties of the CC region
of the DNA. The E sugars of each MTM SA–Trp molecule
are in non-polar contacts only with the A and B sugars
of the other MTM SA–Trp across the dimeric interface. In
addition to non-polar interactions and Zn2+ coordination,
there are nine hydrogen bonds between each DNA strand
and an MTM SA–Trp or a bound water. Six of them are
formed with DNA bases, one with a deoxyribose moiety
and two with phosphate groups. There are three hydrogen
bonds per strand with the bases of the central GC base pair,
which is the core recognition sequence (12). Two of them are
from a Zn2+-coordinated water and the 8-hydroxyl group of
the chromophore to the N2 of the G base. The third hydro-
gen bond is made between the other Zn2+-coordinated wa-
ter and the O2 of the C base (Figure 2C). Two other hydro-
gen bonds are made between the 3- and 4-hydroxyl groups
of the E sugar and the N2 and the N3 of the G base im-
mediately preceding the central GC, and the other base-
directed hydrogen bond is between the 3-hydroxyl group
of the E sugar as a donor of its hydrogen to the O2 of
the 3′-terminal T8/T3’ base of the interacting 6-bp region.
In contrast with the central (G/C)(G/C)-recognizing rigid
chromophore-Zn2+-water scaffold, dictated by the Zn2+ co-
ordination geometry, the flexibility of the saccharide side
chains may allowMTM to adapt to different flankingDNA
sequences, which would explains the lack of sequence pref-
erence of MTM to these flanking sequences (12,33).
Crystal structures of MTM SA–Phe in complex with
AGGGATCCCT and AGGGTACCCT
We recently demonstrated that both of these two palin-
dromic DNA sequences are high-affinity MTM binding se-
quences, as they contain XGGX sites (12). We obtained
crystal structures of these complexes, where Zn2+, as above,
was used to form anMTM SA–Phe dimer and to serve as a
source of the anomalous signal for crystal structure deter-
mination by SAD.The two complexes formed crystals in the
same crystal form, with one MTM SA–Phe–DNA complex
per asymmetric unit. In these crystal structures, each DNA
oligomer was bound to twoMTMdimers (Figure 3). Unex-
pectedly, in each structure one dimer was bound to the first
GG register (i.e. to the AGGG site; Figure 3A and C) and
the other dimer was bound to the second GG register (i.e.
to the GGGT and GGGA on the complementary strand;
Figure 3B and D).
MTM SA–Phe dimers are bound to the AGGG(TA) and
AGGG(AT) sites on the two DNA oligomers very similarly
(Figure 4 and Supplementary Figure S8), and only a few
minor differences are observed, as follows. In the former
case (Figure 4) a hydrogen bond is observed between the
3-hydroxyl group of the E-sugar of one of the MTM SA–
Phe molecules as a hydrogen bond donor and the O2 of
the T base of the AGGGTA region, as was also observed
in the MTM SA–Trp–DNA complex (Figure 2C). In the
complex with AGGG(AT) (Supplementary Figure S8), an
A is in place of the T; here the hydrogen is instead donated
to the O4’ atom of the deoxyribose moiety of the A nu-
cleotide. Unlike the complex with AGGG(TA), this com-
plex also contains a hydrogen bond between the 3-hydroxyl
of the B-sugar of the other MTM SA–Phe monomer and a
phosphate group of the bottom DNA strand. A similar hy-
drogen bond is observed in the MTM SA–Trp–DNA com-
plex. The other interactions appear to be present in both
complexes.
As expected from the non-palindromic nature of se-
quences AGGGTA and AGGGAT, there is a pronounced
interaction asymmetry in the MTM SA–Phe–DNA inter-
actions. The top strand makes a more extensive set of con-
tacts with the MTM analog than does the bottom strand.
All six nucleotides of the AGGG(TA)/(AT) region are en-
gaged in the interactions with the MTM analogue on that
strand, including the A/T nucleotide on the 3′-end of the
region. This interaction is a non-polar contact between the
3-methyl group of the E-sugar and the C4’ and C5’ deoxyri-
bose atoms of the A/T nucleotide. Sugar D of one MTM
SA–Phe molecule in the dimer is engaged in hydrophobic
contacts with the deoxyribose group of the preceding nu-
cleotide, whereas the sugar D groups of MTM SA–Trp are
not engaged in interactions with the palindromic GGCC
site. The core of MTM SA–Phe is also in a more inti-
mate contact with the top strand than for the GGCC site.
For example, the 7-methyl group of one of the MTM SA–
Phe monomers is in non-polar contact with the deoxyri-
bose moiety of the first G of the AGGG motif. The top
strand bias is also observed for the hydrogen bonds: seven
bonds are formed with the top strand and only three with
the bottom one. Remarkably, one of the MTM analogue
monomers in the dimer does not form any hydrogen bonds
with DNA. The MTM SA–Phe core of the other monomer
and the Zn2+−coordinating water molecules are engaged in
five hydrogen bonds with the GGG region, whereas only
two hydrogen bonds are observed between these structural
elements of the MTM analogue and the complementary
strand. The hydrogen bond formed by the 8-hydroxyl of one
of the cores to the N2 amino group of the first G is the same
as that in complex with the GGCC sequence (Figure 2C).
Unlike the latter, the 8-hydroxyl of the other core forms a
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Figure 3. Crystal structures of MTM SA–Phe–DNA complexes. (A) The MTM SA–Phe bound to the first GG register of the AGGGTACCCT oligomer.
(B) The MTM SA–Phe bound to the second GG register of the AGGGTACCCT oligomer in the same complex as in panel A. (C) The MTM SA–Phe
bound to the first GG register of the AGGGATCCCT oligomer. (D) TheMTMSA–Phe bound to the secondGG register of the AGGGATCCCT oligomer
in the same complex as in panel C.
hydrogen bond with the N2 of the second G, an apparent
consequence of the sequence difference. Another hydrogen
bond not observed in the complex with GGCC is also from
the 8-hydroxyl donating its hydrogen to O4′ of the deoxyri-
bose of the second G. Notably, the N2 amino groups of all
three G’s in the AGGG sequence and the N2 amino groups
of all theGbases of both strands of theGGCC sequence are
engaged in hydrogen bonds with the MTM analogues. The
propensity of MTM to satisfy the hydrogen bonding poten-
tial of the N2 amino group was demonstrated previously by
binding studies with DNA containing 2,6-diaminopurine
substitutions (34). Our structures provide an atomic view of
this adaptation to the XGGX sequence by the MTM dimer
core and, ultimately, the basis of the partial disengagement
from the bottom strand and the resulting top strand bias.
The two Zn2+ coordinating water molecules form two hy-
drogen bonds each. One water forms a bifurcated interac-
tion with one strand and the other water forms a bifurcated
interaction with the other strand in the same fashion as ob-
served in the complex ofMTMSA–TrpwithGGCC (except
for bonding to theN3 of G3 in the AGGG sequence in place
of the bond to the O2 of the C6/C5’ in the GGCC sequence;
Figure 2C). The hydrogen bonds to the other strand from
either watermolecule are no longer present in the complexes
with AGGG. The E-sugar groups form some of the same or
similar hydrogen bonds to those observed in the complex
with GGCC. One prominent difference, also reflecting the
bias toward the AGGG strand is that the 3-hydroxyl group
of the E-sugar forms a hydrogen bond with the N2 of G4
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Figure 4. A schematic of the interactions in the complex of MTM SA–Phe with the first GG register of AGGGTACCCT DNA.
instead of the N2 of G7’ on the complementary strand in
the GGCC sequence (Figure 2C).
The binding to the secondGG register by the otherMTM
SA–Phe dimer in each structure (Figure 5 and Supplemen-
tary Figure S9) is best described as a shift of all interac-
tions relative to those with the first GG register, with a
few relatively minor exceptions. Even though more hydro-
gen bonds are formed between the backbone of the bot-
tom DNA strand than for complexes with the other regis-
ter, the overall top strand bias is still present. For example,
eight hydrogen bonds are formed with the top strand and
six with the bottom one. As expected, all core interactions
all shifted by one base pair, maintaining the top strand bias.
An additional weak hydrogen bond is formed between the
8-hydroxyl group and the O4’ of the deoxyribose of C3’.
The E-sugar of the same MTM SA–Phe monomer forms a
hydrogen bond both with N2 and N3 of G2, in keeping with
the previous observations that the N2 of all the G bases are
engaged in the hydrogen bonds with the MTM analogue.
The differences between binding to the GGGTA (Figure
5) and GGGAT (Supplementary Figure S9) sequences are
mainly in the patterns of hydrogen bonding from anE-sugar
to the variable bases. For example, in each case the base at
the 5′ position is engaged in interactions with the E-sugar
moiety (O2 of T5’ or N3 of A5’, respectively).
MTManalogues can bind DNA together with the FLI1 DBD
and affect the stability of FLI1 DBD–DNA complex
Because MTM and its analogues bind GG sites on the
DNA in the minor groove whereas FLI1 DBD binds its
recognition site GGA(A/T) in the major groove (28), we
hypothesized that a molecule of an MTM or its analogue
may bind a FLI1 DBD recognition site non-competitively
with the FLI1 DBD and perturb the stability of the FLI1
DBD–DNA complex. To test this hypothesis, we formed
a FLI1 DBD complex on a 6FAM-labeled DNA contain-
ing six GGAA repeats (AA(GGAA)6) and investigated the
stability of this complex upon titrating in MTM and its
analogues, by measuring fluorescence polarization of the
6FAM probe. This DNA sequence was designed based on
the previous finding that a minimum of five GGAA repeats
was necessary and sufficient for the oncogenic transforma-
tion by EWS–FLI1, driven by binding to these repeats (35).
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Figure 5. A schematic of the interactions in the complex of MTM SA–Phe with the second GG register of AGGGTACCCT DNA.
Binding of the FLI1 DBD to this DNA resulted in an in-
crease in fluorescence anisotropy (Figure 6A). At these con-
ditions ([DNA] = 50 nM, [FLI1 DBD] = 500 nM), DNA
is nearly completely saturated with bound FLI1 DBD. We
then probed the lifetime of these complexes by a heparin
challenge. Heparin is a polyanionic competitor that binds
free FLI1 DBD and prevents it from binding DNA. There-
fore, at high enough concentration heparin drives dissocia-
tion of FLI1 DBD the DNA. Indeed, upon a 10 min chal-
lenge with heparin (at 7.5 g/ml), approximately half of
FLI1–DNA complexes dissociated from the DNA (Figure
6A). We carried out an analogous heparin challenge in the
presence of increasing concentrations of MTM,MTM SA–
Trp andMTMSA–Phe. At 1M,none of these compounds
had an effect on fluorescence anisotropy in the absence of
FLI1 (Figure 6A). We observed that at concentrations of
0.2–1 M, these compounds resulted in a significant in-
crease in fluorescence anisotropy in the heparin challenge
experiment, stabilizing about half of FLI1–DNAcomplexes
that would have dissociated without MTM. Above 0.2 M
this stabilizing effect was progressively weaker with increas-
ing concentration of MTM, and this trend continued at
higher concentrations. These data demonstrate that not
only do MTM and its analogues bind DNA together with
FLI DBD, but at sub-micromolar concentrations they can
have a stabilizing effect on FLI1–DNA complex formation.
To probe directly whether a FLI1–DNA–MTM ternary
complex can form on a short DNA oligomer with a single
FLI1/MTMbinding siteGGAA site and no otherMTMor
FLI1 binding sequences, we acquired HSQC NMR spectra
for an 15N-labeled FLI1 DBD in complex with a double-
stranded DNA 12-mer TTGAAGGAAGAG in the absence
and in the presence of the stoichiometric amount of MTM
SA–Trp (Figure 6B). Additionally, to test a possibility for
interactions of FLI1 DBD with MTM in the absence of
DNA and to consider a potential for MTM to compete
with FLI1 DBD for DNA binding, we collected HSQC
NMR spectra with the 15N-labeled FLI1 DBD alone and
in the presence of MTM SA–Trp (Figure 6C). The reso-
nance signals the FLI1 DBD are well dispersed in all cases,
indicating a stable structure, in agreement with our crys-
tallographic structural studies (28). Upon addition of the
MTManalogue, chemical shifts of the FLI1DBDbound to
DNA undergo significant changes (Figure 6B). The result-
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Figure 6. Formation of a ternary FLI1 DBD–DNA–MTM complex. (A)
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ing spectral pattern (blue resonances in Figure 6B) is dif-
ferent from that of the FLI1 DBD alone (red resonances in
Figure 6C), indicating formation of the ternary FLI1DBD–
DNA–MTM SA–Trp complex, rather than displacement
of the FLI1 DBD from DNA. These spectral differences
show that the FLI1 DBD MTM SA–Trp binding perturbs
the structure of the FLI1 DBD bound to DNA, consistent
with the ternary complex formation observed in the flu-
orescence anisotropy experiments. Furthermore, the spec-
tral patterns of the free FLI1 DBD in the absence and in
the presence of the MTM analogue (Figure 6C) are highly
Figure 7. The crystal structure of FLI1 DBD in complex with the 11-mer
DNA GACCGGAAGTG.
similar, demonstrating that MTM does not interact with
the FLI1 DBD in the absence of DNA. These data are the
first direct demonstration of the formation of ternary FLI1–
DNA–MTM complex.
DNA conformations in the structures of MTM analogue–
DNA complexes and in a structure of FLI1 DBD in complex
with 11-mer DNA GACCGGAAGTG DNA
To analyze whether MTM binding perturbs the DNA con-
formation and whether MTM has a potential to affect
FLI1–DNA binding through these DNA conformational
changes, we analyzed the DNA conformations in our struc-
tures of MTM analogue–DNA complexes and in a new
crystal structure of FLI1 DBD in complex with an 11-mer
DNA containing a single FLI1 binding site GGAA, by us-
ing 3DNA software (32). The crystals of this FLI1 DBD–
DNA complex were in a new crystal form, yielding a higher
resolution structure (Figure 7) than our previously reported
structure of FLI1 DBDwith a one base pair shorter 10-mer
ACCGGAAGTG (28). TheDNAbinding and dimerization
properties of the FLI1 DBD were described in that study.
These properties are very similar in our new crystal struc-
ture; therefore, here we will consider only the conformation
of the DNA in complex with FLI1 DBD.
Binding ofMTMSA–Phe to two different registers of the
same DNA sequence allows us to observe potential effects
of binding of this MTM analogue on DNA conformation
(Figure 8). The DNA conformations of AGGGTACCCT
and AGGGATCCCT oligomers in complex with MTM
SA–Phe differ, at least in part, due to the different sequences
of these two oligomers. Nevertheless, the general behav-
ior of several parameters that exhibit the largest variation
of values along the DNA is similar for the two DNA se-
quences. Several parameters, such as buckle, propeller and
the widths of the major and minor grooves, vary signif-
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icantly along the DNA and exhibit a pronounced asym-
metry with respect to the middle of the DNA. This asym-
metry indicates the two MTMs exert different effects on
DNA conformation by binding to different registers of the
oligomers. Binding ofMTMSA–Phe to the secondGG reg-
ister (GGG(T/A)) is associated with positive buckle val-
ues, whereas binding to the first GG register (AGGG),
close to the DNA end, is associated with negative buckle
values. Propeller values are negative, but increase toward
the zero value asymmetrically, also likely as a result of
the asymmetry of MTM analog binding. The DNA ma-
jor groove is compressed asymmetrically with respect to the
middle of the DNA oligomer. On the other hand, the mi-
nor groove is widened throughout the DNA, which could
be either a result of MTM binding or an intrinsic prop-
erty of the sequence. In assessing whether these potential
conformational effects of the MTM analogue binding to
a GGA(A/T) site could favor or disfavor FLI1 binding to
the same site, we compared structural parameter values for
binding of the MTM analog to the second DNA register, in
other words, the GG of the GG(T/A) sequences, to the val-
ues for the GGAA sequence in the FLI1 DBD–DNA struc-
ture (Figure 8E and F). The buckle values of the GGAA re-
gion bound to FLI1 are positive, as with the GG(AT)/(TA)
conformation in theMTMSA–Phe–DNA complex. Again,
for both FLI1 DBD andMTM analogue binding the DNA
major groove is compressed. This effect is stronger as a
result of MTM analog binding, as the major groove has
the same width as the minor groove in the MTM analogue
DNA complexes. In both FLI1 DBD– and MTM analog–
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DNA complexes the minor grooves of the binding sites are
widened. In summary, conformational perturbations that
appear to be caused byMTM SA–Phe binding to DNA are
consistent with FLI1 DBD binding to the same site.
MTM conformations in the structures of MTM analogue–
DNA complexes
To establish if MTM analogues also undergo DNA
sequence-dependent structural adaptation upon binding
DNA, we superimposed cores of one of MTM analogue
monomers in different complexes and compared the con-
formations of the cores and the side chains in different
dimers. The conformations of the dimeric cores of the
MTM analogues in the complexes with the GGCC and
AGGG sites (the first GG register in either AGGGT or
AGGGA sequences) are nearly identical. The disaccharide
and the trisaccharide appendages exhibit greater conforma-
tional plasticity (Figure 9A). The largest atomic positional
differences of ∼2.5 A˚ are observed for the E-sugars, the
most distant groups from the cores. These conformational
differences of the disaccharide and the trisaccharide tails
are consistent with the minor differences in the DNA back-
bone conformations of these regions, especially for the mid-
dle GC and GG in the GGCC and AGGG sequences, re-
spectively. The 3-side chains are either solvent-exposed (in
MTM SA–Phe) or are involved in crystal packing interac-
tions (in MTM SA–Trp). These side chains adopt some-
what different conformations dictated by their environment
in the respective crystals.
The MTM SA–Phe bound to the GGG(T/A) sites, in
other words, to the secondGG register exhibits much larger
conformational differences from that bound to the first GG
register or from MTM SA–Trp bound to the GGCC site
(Figure 9B). These differences appear to follow the large
DNA conformational differences between the two halves
of the DNA oligomers described in the previous section.
While the positions of the Zn2+ and the coordinating wa-
ter and oxygen atoms are essentially unchanged, one of the
cores is rotated toward the other core by ∼18◦. This rota-
tion is a superposition of a rotation around the axis go-
ing through the Zn2+ perpendicular to the chromophore
plane and a rotation around the axis parallel to the Zn2+-
coordinating oxygens. The conformations of the tri- and di-
saccharide tails of the two MTM monomers point toward
the center DNA end are quite similar, with atomic position
shifts not exceeding ∼1.5 A˚. In contrast, significant confor-
mational differences between the tails are observed on the
other side of the cores. For example, these trisaccharide tails
are shifted relative to one another by∼3.9 A˚, and the disac-
charide tails are shifted by ∼3.1 A˚. These observations in-
dicate thatMTManalogues, like DNA, undergo conforma-
tional changes upon formation of MTM–DNA complexes.
DISCUSSION
Small molecules that could regulate transcription of specific
genes in therapeutic or research applications are highly at-
tractive, but they have not yet been developed. Initiation
of transcription has been recognized to be a kinetic bot-
tleneck in the entire gene expression pathway (36); there-
fore, transcription initiation represents both a highly regu-
lated process and an excellent target for chemical inhibition.
Transcription in bacteria and human is targeted by clini-
cally used drugs, such as rifampicin and trabectedin, respec-
tively. While rifampicin interacts directly with the bacte-
rial RNA polymerase, trabectedin forms a covalent adduct
with DNA, which disrupts proper function of RNA poly-
merase II and DNA binding transcription factors. An in-
dividual transcription factor generally regulates a relatively
small set of promoters and, in that regard, it appears to be
a promising target for small molecules. However, the DNA
or protein binding surfaces of transcription factors typically
lack small hydrophobic cavities suitable for binding drug-
like compounds and, for this reason, transcription factors
have been viewed as undruggable. On the other hand, small
molecules that bind DNA do not recognize a long enough
DNA sequence to be specific, and binding to multiple sites
leads to off-target effects and toxicity. Synthetic polymeric
molecules, such as polyamides, that would bind in the mi-
nor groove of the DNA over a sufficiently long DNA se-
quence to ensure specificity to compete off transcription
factors are being developed (37). However, sequence recog-
nition from the minor groove is limited by poor accessibil-
ity of DNA bases from that groove. A molecule that would
combine chemical features responsible for DNA binding
and transcription factor binding would be very desirable.
DNA binding natural products are potential candidates for
development of such bifunctional molecules, as they gener-
ally have favorable pharmaceutical properties, they are large
enough to have some DNA sequence preference and they
can contain groups that could be chemically elaborated to
install protein interacting functionalities.
MTM is a highly potent antagonist of oncogenic tran-
scription factor EWS–FLI1 in ES. Off-target toxicity of
MTM, likely due to its low DNA sequence specificity (an
MTM-box X(G/C)(G/C)X is sufficient for tight MTM
binding (12)), poses a barrier in developing MTM as a clin-
ically useful anti-cancer agent. However, MTM is chemi-
cally complex, containing groups that can be modified by
semi-synthetic methods to yield analogues with superior
anti-cancer or toxicity properties (8–10,12,38–41). Basic un-
derstanding of the molecular mechanism of MTM binding
to DNA and its interference with transcription is necessary
to improve MTM analogues in a rational fashion. A set of
crystal structures of novel MTM analogues, MTM SA–Trp
andMTMSA–Phe bound to four differentMTM-boxes re-
ported here provides a rationale for and detailed structural
view of the MTM-box recognition by MTM. For example,
non-palindromic sequences are recognized through the bias
toward G bases. We also demonstrate that both MTM and
DNA alter their conformations upon complex formation,
a phenomenon that is common in protein–DNA recogni-
tion. MTM binds DNA in the minor groove, whereas ETS-
family transcription factors including FLI1 (28) or its close
relative ERG (42) bind DNA in the major groove, which
has prompted us to hypothesize that MTM can modulate
functions of these transcription factors by binding DNA
together with them, instead of competing with them by oc-
cluding some of the protein binding surface on the DNA.
Then the effect of MTM or its analog on the transcrip-
tion function could be allosteric, through the DNA con-
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Figure 9. Superimposition of MTM analogues in different complexes with DNA. (A) Superimposition of MTM SA–Trp (light-gray)-DNA and MTM
SA–Phe (dark-gray)-AGGGTACCCT (first GG register). (B) Superimposition of MTM SA–Phe (dark-gray)-AGGGTACCCT (first GG register) with
MTM SA–Phe (light-gray)-AGGGTACCCT (second GG register).
formational changes, such as those observed in this study
by NMR, or through direct interactions between an MTM
analogue and the transcription factor. Indeed, we found
that MTM and its analogues had a stabilizing effect on
the FLI1 DBD bound to a repeating GGAA sequence,
which is critical for the oncogenic function of EWS–FLI1
at some promoters. One of theMTM analogue–DNA com-
plexes that we structurally characterized was formed on the
GGAT sequence (Figure 3D), an ETS-family recognition
sequence. Even though the conformations of theGGAT site
are generally comparable in the MTM SA–Phe and FLI1
DBD complexes, they are not the same (Figure 8): there are
differences both in the backbone and base conformations.
Therefore, the conformation of the DNA in the ternary
complex is likely a compromise between these two confor-
mations. The conformations of the DNA boundMTM and
FLI1 in the ternary complex with DNA must then also be
somewhat different from those in the respective binary com-
plexes. These changes or even direct interactions between
the MTM analog and FLI1 may account for the chemical
shift changes observed in the NMR experiments (Figure 6).
Future determination of the structure of the ternary com-
plex will shed light on the exact nature of these conforma-
tional changes.
In order to understand howMTMandFLI1may interact
on DNA, by using the structure of MTM SA–Phe in com-
plex with the GGAT site and the structure of FLI1 DBD–
DNA complex, we constructed structural models ofMTM–
DNA–FLI1 complexes.Wemade structural models of three
ternary complexesMTMSA–Phe–DNA–FLI1DBDby su-
perimposing the DNA in these two structures in differ-
ent DNA registers, which would correspond to sequence
GGAAGGAAGG (Figure 10). In these structures the FLI1
DBD is bound to the interior GGAA site, and DNA is su-
perimposed in three different registers so that MTM SA–
Phe is bound to the upstream GG (Figure 10A), the middle
GG (Figure 10B) and the downstream GG (Figure 10C).
The MTM analogue interacts with FLI1 DBD differently
in these three registers. When bound to the same GG as
the FLI1–DBD (Figure 10B), theMTManaloguemakes no
direct contacts with the protein; any interactions would be
transmitted through DNA conformational changes. These
interactions, in principle, can be favorable and stabilize the
protein–DNA complex. One of such stabilizing conforma-
tional changes may be the major groove narrowing that we
observed in both FLI1 DBD–DNA and MTM analogue–
DNA complex. The upstream bound MTM analogue does
not exhibit severe steric clashes with the protein (Figure
10A) and can interact with the protein directly through its 3-
side chain or its B-sugar moiety. Such interactions, in prin-
ciple, can either stabilize or destabilize the protein–DNA
complex, depending on the chemical nature of the interact-
ing groups on the MTM analogue. The 3-side chain stands
out as an antenna-like structural feature that could be op-
timized for specific interactions with transcription factors
such as FLI1 or ERG, in addition to the effect of this side
chain on DNA binding (12). In contrast, the MTM ana-
logue bound downstream (Figure 10C) severely clashes with
the protein and is likely to act as a competitor. The last
mode of binding can serve as an explanation of the observed
destabilizing effect of MTM analogues on FLI1 DBD–
DNA complexes at concentrations above 1 M. Detailed
structural and biochemical studies of ternary complexes of
MTM analogues, FLI1 DBD and DNA are needed to test
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Figure 10. Structural models of the MTM SA–Phe–DNA–FLI1 DBD complex with GGAA repeats. (A) The MTM analogue bound to the upstream GG
site. (B) The MTM analogue bound to the same GG site as the FLI1 DBD. (C) The MTM analogue bound to the downstream GG site. The respective
binding sites for the MTM analogue and the FLI1 DBD are shown schematically on the bottom.
these models and obtain a more accurate picture of MTM
effects on transcription factors.
In summary, this study clarified the structural basis of
MTM analogue–DNA recognition and demonstrated com-
plex effects of MTM binding to DNA on the stability of
FLI1–DNA complexes. The structural models of ternary
complexes of MTM analogue–DNA–FLI1 DBD provided
a potential explanation for these effects. These models and
future experiments testing them will be invaluable in de-
veloping transcription factor-selective MTM analogues for
their use as chemical probes and anti-neoplastic agents in
clinic.
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